NCT01740258View on ClinicalTrials.gov

Bevacizumab Beyond Progression (BBP)

PHASE2CompletedINTERVENTIONAL

Enrollment

68

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

November 14, 2019

Study Completion Date

November 14, 2019

Conditions

Malignant GliomaGrade 4 Malignant GliomaGlioblastomaGliosarcoma

Interventions

RADIATION

Radiation Therapy

DRUG

Temozolomide

DRUG

Bevacizumab

Trial Locations (1)

27710

Duke Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Duke University

OTHER

NCT01740258 - Bevacizumab Beyond Progression (BBP) | Biotech Hunter | Biotech Hunter